NAD+ IV Drips: Are They Worth £550 a Session or Just Expensive Hype?

Clinics across the UK are charging up to £550 a session to drip NAD+ directly into your veins, promising to reverse ageing at a cellular level. But leading scientists are now urging caution — and the evidence may point to a much cheaper alternative. Here is what you actually need to know before booking an appointment.

Something unusual is happening in the corridors of London’s private clinics. Executives and high earners are quietly booking themselves in for NAD+ IV drips — intravenous infusions that promise to slow or even reverse biological ageing. The sessions cost between £275 and £550 each. And they are selling out. [The Independent, 2026]

But here is the question nobody in that waiting room is asking loudly enough: does the science actually support any of this?

New research covered by NPR and produced in collaboration with Harvard Medical School confirms one thing beyond doubt. NAD+ levels — NAD+ stands for nicotinamide adenine dinucleotide, a molecule your cells use to produce energy — do fall significantly as we age. [NPR / Harvard Medical School, May 2026]

That decline is real. It is measurable. And it does appear to be linked to many of the things we associate with getting older: fatigue, slower recovery, and reduced cellular repair.

The problem is what comes next. Because the fact that NAD+ declines with age does not automatically mean that topping it up reverses that ageing process. And this is where the honest science parts company with the marketing.

What Harvard researchers are actually saying

Leading scientists at Harvard Medical School are now publicly warning that the evidence for NAD+ IV drips reversing biological age in humans remains limited. [NPR / Harvard Medical School, May 2026]

That is a careful, measured statement. It does not say the treatments are useless. It says the human evidence is not yet strong enough to justify the claims — or the price tag.

To understand why, it helps to know a little about how NAD+ works in the body. Your cells cannot simply absorb NAD+ whole. The molecule is too large to pass through cell membranes easily. So when you receive an IV drip of NAD+ directly into your bloodstream, your body has to break it down first and then rebuild it inside the cells. [The Independent, 2026]

This is why the delivery method matters enormously, as doctors interviewed by The Independent have now made clear. Injecting NAD+ directly may not be the most effective route at all. [The Independent, 2026]

Your body may simply break it down, use the parts for something else, and move on.

So what does the more promising evidence actually show?

This is where it gets genuinely interesting — and where the research starts to point in a different direction entirely.

Rather than taking NAD+ directly, scientists are increasingly interested in what are called precursors. A precursor is simply a building block — a substance your body uses to make something else. In this case, to make NAD+ itself.

The two precursors attracting the most serious scientific attention right now are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are smaller molecules. Both cross into cells more easily than NAD+ itself. And both show more promise in human clinical studies than direct NAD+ infusions. [The Independent, 2026]

Human trials of NMN have shown it can raise NAD+ levels in the blood measurably. A study published in the journal Science found that NMN supplementation improved muscle insulin sensitivity in older women. [Science, 2021, via NPR reporting]

That is meaningful. But scientists are careful to note that raising NAD+ levels in the blood is not the same as reversing ageing. We do not yet have long-term human data showing that these supplements extend healthy life. [NPR / Harvard Medical School, May 2026]

The UK company trying to do this properly

Not everyone in this space is selling hope without evidence. A Newcastle-based biotech company called Nuchido is developing what it describes as a next-generation NAD+ boosting supplement. Crucially, the company says its approach is backed by peer-reviewed research — research that has been independently checked and published in scientific journals. [Nuchido, 2026]

Nuchido’s approach focuses not just on supplying precursors but on supporting the body’s own NAD+ production pathways. The idea is to work with the body’s existing machinery rather than simply flooding it with raw materials.

The global NAD+ anti-ageing market is projected to grow at 13.5 percent every year until 2034. [Nuchido market analysis, 2026] That is an enormous amount of money chasing a field where the human evidence is still catching up with the enthusiasm.

Nuchido’s existence — and its focus on peer-reviewed backing — suggests there is a more rigorous tier emerging within an industry that has not always covered itself in scientific glory.

What should you actually do with this information?

If you are considering NAD+ IV drips at £275 to £550 a session, here are the honest questions worth asking before you hand over your card details.

First, ask the clinic what specific human clinical trial evidence they are basing their claims on. Not animal studies. Not theoretical mechanisms. Human trials with published results.

Second, ask whether their practitioners can explain why an IV drip would be more effective than an oral precursor supplement, given what the current science says about how NAD+ is absorbed.

Third, consider whether the money would be better spent on things with much stronger evidence behind them. Regular exercise, for example, has been shown in multiple large human studies to raise NAD+ levels naturally. [NPR / Harvard Medical School, May 2026]

That does not mean NAD+ research is not exciting. It genuinely is. The science linking NAD+ decline to ageing is real, and the research into precursors like NMN and NR is producing interesting early results.

But there is a significant gap between “interesting early results” and “worth £550 of your money per session right now.” And the researchers doing this work are the first people to tell you that.

The bottom line

NAD+ levels do fall as we age. That is confirmed. NAD+ IV drips are an expensive and fashionable response to that fact — but leading scientists warn the evidence for their effectiveness in humans is still limited. [NPR / Harvard Medical School, May 2026]

Precursor supplements like NMN and NR currently have more supportive human data than direct IV infusions. UK companies like Nuchido are trying to build products on peer-reviewed science rather than trend-chasing. And exercise remains the most evidence-backed way to support NAD+ levels that most of us already have access to.

The biology here is fascinating. The treatments may well improve. But right now, the honest answer is: the science is promising, the marketing has run far ahead of it, and you deserve to know the difference.

This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.